ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships

June 5, 2017
Western and China companies are leveraging the significant funding and support available in China to develop their assets more cost effectively and efficiently. 2016 set another record in VC funds raised (USD 15 billion) and invested (USD 5.8 billion) in life science in China. And partnering activity has continued to be strong, with over USD 8 billion in deal value created in 2015 and 2016. Highly active VCs, CROs and Western and China pharma companies discuss how they can serve as financial and strategic partners.
Previous Article
Where are they now? EpiAxis Therapeutics channels successes into scientific and business development
Where are they now? EpiAxis Therapeutics channels successes into scientific and business development

EpiAxis Therapeutics is channeling its success at BioPharm America™’s Startup Day into success at the busin...

Next Video
ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?
ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?

Everything in China seems to be on the fast track. This is especially true in the pharma industry, where ne...